Abiopharma

🔍 Koopmans Chris (Executive)

Company: Marvell Technology, Inc. (MRVL)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 4,498 shares of Common Stock (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 138,368.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,231 shares of Common Stock at $134.6 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 136,137.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Acquired 2,788 shares of Common Stock (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 138,925.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,383 shares of Common Stock at $134.6 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 137,542.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Acquired 4,077 shares of Common Stock (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 141,619.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,022 shares of Common Stock at $134.6 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 139,597.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Acquired 158,659 shares of Common Stock (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 298,256.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 78,664 shares of Common Stock at $134.6 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 219,592.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Acquired 40,799 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 40,799.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5
• Sold 4,498 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F6, F6
• Sold 2,788 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,150.00 | transaction_form_type: 4 | Footnotes: F4, F7, F7
• Sold 4,077 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 32,616.00 | transaction_form_type: 4 | Footnotes: F4, F8, F8
• Sold 158,659 shares of Performance Stock Units (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F9, F10, F10

Footnotes:

• F1: Shares held by the Christopher R. Koopmans and Heather J. Koopmans Family Trust.
• F2: Surrender of shares in payment of tax withholding due as a result of the vesting of restricted stock units.
• F3: Surrender of shares in payment of tax withholding due as a result of the vesting of performance stock units.
• F4: Each restricted stock unit represents a contingent right to receive one share of Common Stock of Marvell Technology, Inc. upon vesting.
• F5: The restricted stock units shall vest in equal quarterly installments over a three-year period and were granted pursuant to the annual equity grant program.
• F6: This award fully vested on April 15, 2026.
• F7: The remaining restricted stock units shall vest on July 15, 2026, October 15, 2026, January 15, 2027 and April 15, 2027.
• F8: The remaining restricted stock units shall vest on July 15, 2026, October 15, 2026, January 15, 2027, April 15, 2027, July 15, 2027, October 15, 2027, January 15, 2028 and April 15, 2028.
• F9: Each performance stock unit represents a contingent right to receive one share of Common Stock of Marvell Technology, Inc. upon vesting.
• F10: Reflects the number of shares earned with respect to performance stock units that fully vested on April 15, 2026. The achievement levels of the performance metrics applicable to the award and the number of shares earned based on such results were certified on April 15, 2026.